Muscarinic Agonists In September 2024, the U.S. Food and Drug Administration approved xanomeline and trospium chloride (Cobenfy) capsules to treat adults with schizophrenia.e60dc2a1-f33c-4a05-9b50-8e3e8e5976293a735644-9397-4d7d-8971-e2ee91506704 The first schizophrenia drug approved in decades, Cobenfy is the first in a new class of antipsychotic drugs called muscarinic agonists. Cobenfy works differently than other antipsychotics by targeting cholinergic receptors in the brain. Other antipsychotics for schizophrenia work by targeting dopamine, which has been the standard of care for…

Read the full article at EVERYDAYHEALTH.COM